Anaemia Clinical Trial
— PREVENTTOfficial title:
A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Anaemia Undergoing Major Open Abdominal Surgery
Verified date | May 2019 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anaemia is a common problem in patients undergoing surgery. About half of patients undergoing
a major operation have anaemia, often a consequence of the disease requiring surgery. Anaemia
causes patients to feel tired and unwell. Anaemia at the time of surgery increases the
requirement for blood transfusion (50% if anaemic compared to only 15% without anaemia). Both
anaemia and blood transfusions are associated with increased complications from surgery,
delayed recovery and prolonged hospital stay. The investigators propose that giving
intravenous iron before operation can be used to correct anaemia in these patients.
Consequently if patients are not anaemic they are less likely to need blood transfusion. Also
patients feel better and their health is improved before their operation they are more likely
to tolerate the surgery, recover faster, be less likely to have complications from surgery
and return home sooner. This will have benefits to the individual patient and also to the NHS
by reducing costs.
Oral Iron tablets are not effective as they take 3-6 months to increase blood levels, the
tablets are often not tolerated as cause constipation or stomach pain, overall only 30-50% of
people continue taking oral iron. A full treatment dose of intravenous iron can be given in
15 minutes with minimal side effects. The effect is to rapidly increase blood counts in 2-4
weeks. The investigators propose that this treatment can be incorporated to patient
preparation pathways for surgery as an outpatient without the need for additional visits to
hospital.
Small studies have suggested a benefit of iron therapy in orthopaedic and gynaecological
surgery. This study will look at 500 patients undergoing major surgery at 20 hospitals in the
UK. The investigators anticipate half of patients treated will have their anaemia corrected
before operation. Patients with anaemia will be identified as part of the routine blood tests
taken preoperatively and invited to take part in the study. Following informed consent, they
will be randomly allocated to receive either intravenous iron or a placebo infusion of
saline. Intravenous iron is a dark liquid given continuously into a vein over 15 minutes. To
ensure neither doctor nor patient knows which treatment is being given both infusions will be
prepared and administered by an unblinded authorised person via a black bag through black
tubing. There will be no other changes to the patient's normal treatment.
The main aim of this study is to assess if intravenous iron will reduce the need for blood
transfusion in the time period around the operation. Further outcome measures will include;
patient-reported quality of life, complications, length of hospital stay, and cost. Outcomes
will be assessed both during hospital stay and after the patient has been discharged. The
trial will be run through a Clinical Trials Unit with considerable experience in conducting
large trials. The team has a large range of experience in anaemia management and assessment
of complications, quality of life and the cost of health care.
The main aim of this study is to assess if intravenous iron will reduce the need for blood
transfusion in the time period around the operation. Further outcome measures will include;
patient-reported quality of life, complications, length of hospital stay, and cost. Outcomes
will be assessed both during hospital stay and after the patient has been discharged. The
trial will be run through a Clinical Trials Unit with considerable experience in conducting
large trials. The team has a large range of experience in anaemia management and assessment
of complications, quality of life and the cost of health care.
Status | Completed |
Enrollment | 487 |
Est. completion date | May 2019 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. At least 18 years of age and signed written informed consent. 2. Patients undergoing elective major open abdominal surgery. - The Indication for operation may be for benign or malignant disease. - Major Surgery is defined as an operation of anticipated duration more than one hour. 3. Screening haemoglobin (Hb) greater than or equal to 90 g/L (9.0 g/dL) but below or equal to 120 g/L (12.0 g/dL) in women or 130 g/L (13.0 g/dL) in men within four weeks of randomisation. 4. Randomisation and administration of study infusion a minimum of 10 days and maximum 42 days before planned operation. 5. Negative pregnancy test for women of childbearing potential (within last 7 days), and agree to use effective form of contraception until 6 weeks post treatment. 6. Laboratory data used for determination of eligibility at the baseline visit must not be older than four weeks. Exclusion Criteria: 1. Patients undergoing laparoscopic surgery. 2. Body weight under 50kg. 3. Known history of acquired iron overload, or family history of haemochromatosis or thalassemia or TSAT > 50%. 4. Known reason for anaemia (e.g. untreated B12 or folate deficiency or haemoglobinopathy). 5. Known hypersensitivity to ferric carboxymaltose (Ferinject®) or its excipients. 6. Temperature > 37.5 degrees celsius or patient on non-prophylactic antibiotics 7. Known chronic liver disease 8. If clinically indicated for the patient to have LFT's as part of pre-assessment for surgery and this screening alanine transaminase (ALT) or aspartate transaminase (AST) is above three times the upper limit of the normal range. 9. Received erythropoietin or i.v. iron therapy in the previous 12 weeks. 10. Immunosuppressive therapy (for organ transplantation) or renal dialysis (current or planned within the next 12 months). 11. Patients with severe asthma or severe allergy (requiring hospitalisation within the last 12 months). 12. Unfit for elective surgery. 13. Pregnancy or lactation. 14. Inability to fully comprehend and/or perform study procedures in the investigator's opinion. 15. Patient involvement in another IMP trial within the previous 4 weeks, prior to randomisation. Involvement in another IMP trial, following randomisation, that may impact on the results of the PREVENTT trial. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Basildon University Hospital | Basildon | |
United Kingdom | Blackpool Teaching Hospitals | Blackpool | |
United Kingdom | Southmead Hospital | Bristol | |
United Kingdom | Broomfield Hospital | Broomfield | |
United Kingdom | Countess of Chester Hospital | Chester | |
United Kingdom | Russells Hall Hospital | Dudley | |
United Kingdom | Royal Infirmary of Edinburgh | Edinburgh | |
United Kingdom | Queen Elizabeth Hospital | Gateshead | |
United Kingdom | Hereford County Hospital | Hereford | |
United Kingdom | Hillingdon Hospital | Hillingdon | |
United Kingdom | St James's Hospital | Leeds | |
United Kingdom | Aintree University Hospital | Liverpool | |
United Kingdom | Liverpool Women's Hospital | Liverpool | |
United Kingdom | Guy's and St Thomas' Hospital | London | |
United Kingdom | Imperial College Hospital | London | |
United Kingdom | King's College Hospital | London | |
United Kingdom | Royal Marsden | London | |
United Kingdom | University College London | London | |
United Kingdom | James Cook University Hospital | Middlesbrough | |
United Kingdom | Queen's Medical Centre | Nottingham | |
United Kingdom | Pennine Acute Hospitals | Oldham | |
United Kingdom | John Radcliffe Hospital | Oxford | |
United Kingdom | Peterborough and Stamford Hospitals | Peterborough | |
United Kingdom | Salford Royal | Salford | |
United Kingdom | Northern General Hospital | Sheffield | |
United Kingdom | Southampton General Hospital | Southampton | |
United Kingdom | Morriston Hospital | Swansea | |
United Kingdom | Royal Cornwall Hospital | Truro |
Lead Sponsor | Collaborator |
---|---|
University College, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Risk of blood transfusion or death | Co-primary outcome | From randomisation until 30-days following the index operation | |
Primary | Blood transfusion rate (including repeat transfusions) | Co-primary outcome | From randomisation until 30-days following the index operation | |
Secondary | Change in haemoglobin levels | From randomisation to (i) day of index operation, (ii) 8-weeks post index operation and (iii) 6 months post index operation | ||
Secondary | Total number of units of blood or blood products cross matched, total number of packed red cells and any blood products transfused | From randomisation to 30 days post index operation | ||
Secondary | Post operative morbidity survey (POMS) outcomes (outcomes will be presence of morbidity defined by the domains of the POMS e.g. gastrointestinal, cardiovascular) | At days 3, 5, 7 and 14 following the index operation | ||
Secondary | Health-related quality of life: Change in The Multidimensional Fatigue Inventory (MFI) questionnaire total score | From baseline to the 10 day assessment and at 8 weeks and 6 months post operatively | ||
Secondary | Health-related quality of life: Change in European Quality of Life: 5 Dimensions-5 Levels (EQ-5D-5L) questionnaire total score | From baseline to the 10 day assessment and at 8 weeks and six months post operatively | ||
Secondary | Health-related quality of life: Change in Single Question Outcome Measure (SQOM) | From baseline to the 10 day assessment and at 8 weeks and six months post operatively | ||
Secondary | Health resource utilisation | Pre-admission, during admission for index operation, 8 weeks post index operation, and 6 months post index operation | ||
Secondary | Calculated direct, indirect and total costs for the NHS from two perspectives (payer's and societal perspective) | From baseline to 6 months post-surgery | ||
Secondary | Cost effectiveness of treatment options using relevant effectiveness parameters | From baseline to 6 months post-surgery | ||
Secondary | Any reaction or side effect from trial therapy | |||
Secondary | Any reaction or side effect from whole blood or blood product, transfusion reaction | |||
Secondary | Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) | |||
Secondary | Length of hospital stay | |||
Secondary | Mortality | 8 weeks and 6 months post-operatively | ||
Secondary | Readmission | Within 8 weeks and within 6 months of the index operation | ||
Secondary | Blood transfusion | From randomisation to 8 weeks and 6 months post-operatively | ||
Secondary | Change in e-GFR |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05682326 -
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
|
Phase 3 | |
Completed |
NCT03400033 -
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
|
Phase 3 | |
Completed |
NCT02879305 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
|
Phase 3 | |
Completed |
NCT02876835 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
|
Phase 3 | |
Terminated |
NCT02801162 -
Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard
|
N/A | |
Completed |
NCT02288637 -
Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product
|
N/A | |
Completed |
NCT00276224 -
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
|
N/A | |
Completed |
NCT00857077 -
Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana
|
N/A | |
Completed |
NCT06080555 -
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
|
Phase 1 | |
Completed |
NCT01977573 -
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
|
Phase 2 | |
Completed |
NCT02243306 -
Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
|
Phase 1 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00140517 -
Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance
|
N/A | |
Completed |
NCT03239522 -
Absorption and Elimination of Radiolabeled Daprodustat
|
Phase 1 | |
Completed |
NCT01376232 -
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)
|
Phase 1 | |
Completed |
NCT02019719 -
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02969655 -
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02637102 -
The UK CAVIAR Study
|
||
Completed |
NCT01454752 -
Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition
|
N/A | |
Completed |
NCT01136850 -
Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea
|
Phase 3 |